Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Prevention and treatment of hypokalemia,Replacement of potassium, fluid, and electrolytes in patients requiring intravenous therapy
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 m Eq potassium per hour; maximum infusion rate: 20 m Eq/hour (not to exceed 1 m Eq/kg/hour); concentration not to exceed 80 m Eq/L via peripheral line. Each 1 L of this product contains 5 m Eq potassium chloride, 50 g dextrose, and 77 m Eq sodium chloride.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable for endogenous potassium; infused potassium distributes with a rapid initial phase (~1 h) and a slower terminal phase (~8-12 h) reflecting cellular equilibration
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is not metabolized; it is excreted renally. Dextrose is metabolized to carbon dioxide and water via glycolysis and oxidative phosphorylation. Sodium and chloride are excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >90% as potassium ion; minor fecal loss <10%
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Minimal; <5%
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.2-0.5 L/kg, reflecting extracellular and intracellular distribution
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: ~90% (well absorbed); IV: 100%
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR 10-50 m L/min: use with caution, monitor potassium levels closely; GFR <10 m L/min: avoid use or reduce dose to prevent hyperkalemia. Potassium supplementation is generally not recommended in severe renal impairment unless documented hypokalemia.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dosing adjustment required for Child-Pugh class A, B, or C. Monitor serum potassium as hepatic impairment may affect acid-base balance.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Dose determined by age, weight, and serum potassium; typical infusion rate: 0.5-1 m Eq/kg over 1 hour; maximum daily dose: 3 m Eq/kg/day; maximum infusion rate: 1 m Eq/kg/hour. Use in children only if hypokalemia is documented and monitored.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution due to age-related decline in renal function; monitor renal function and serum potassium; consider lower initial doses and slower infusion rates (e.g., 5-10 m Eq/hour).
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
NO BLACK BOX WARNINGS FOR THIS PRODUCT.
None.
Administration may cause hyperkalemia, especially in patients with renal impairment, or with rapid infusion.,Use with caution in patients with cardiac disease, conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, acidosis), or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs.,Monitor serum potassium, glucose, and electrolytes regularly.,Do not administer unless solution is clear and container is intact.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Renal failure (severe or anuria),Severe metabolic acidosis,Concurrent use of potassium-sparing diuretics or potassium supplements (unless closely monitored),Addison's disease
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados) and potassium-containing salt substitutes while receiving this infusion, unless specifically instructed by your physician. Also, limit sodium intake if hypertensive or edematous.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride, dextrose, and sodium chloride are not teratogenic. There is no evidence of fetal risk from electrolyte and fluid administration at recommended doses. However, maternal electrolyte imbalances (e.g., hyperkalemia, hyperglycemia, hypernatremia) can adversely affect the fetus. Use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium, dextrose, and sodium are normal components of breast milk. Potassium chloride and sodium chloride are excreted into breast milk but are not expected to cause adverse effects in nursing infants. No M/P ratio is available; however, these substances are naturally present. Use with caution only if clearly needed.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No standard dose adjustment required; pregnancy does not significantly alter pharmacokinetics of potassium, dextrose, or sodium. Dose based on individual electrolyte and fluid needs, with careful monitoring to avoid maternal electrolyte disturbances that could affect the fetus.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor serum potassium and glucose levels during infusion, especially in renal impairment or diabetic patients. Use with caution in patients on digoxin, as hyperkalemia can precipitate digoxin toxicity. Do not administer concentrated potassium solutions peripherally; typical maximum peripheral concentration is 10 m Eq/100 m L. Check for vein irritation or phlebitis at infusion site. Use a volumetric pump to control infusion rate; rapid infusion can cause cardiac arrest.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication contains potassium, dextrose (sugar), and sodium chloride (salt), administered intravenously to replenish electrolytes and provide calories.,Tell your healthcare provider if you have kidney disease, heart problems, diabetes, or are on medications such as ACE inhibitors, ARBs, or potassium-sparing diuretics.,Report any symptoms of high potassium (muscle weakness, irregular heartbeat, tingling) or high blood sugar (increased thirst, frequent urination, confusion) immediately.,Do not consume potassium-rich foods or salt substitutes without consulting your doctor, as this may increase the risk of hyperkalemia.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 m Eq potassium per hour; maximum infusion rate: 20 m Eq/hour (not to exceed 1 m Eq/kg/hour); concentration not to exceed 80 m Eq/L via peripheral line. Each 1 L of this product contains 5 m Eq potassium chloride, 50 g dextrose, and 77 m Eq sodium chloride.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are not teratogenic. There is no evidence of fetal risk from electrolyte and fluid administration at recommended doses. However, m. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.